Back
Delhi HC Upholds Dr Reddy’s Semaglutide Export Order
In a significant victory for Indian generic pharmaceutical powerhouse Dr Reddy’s Laboratories Limited, the ’s Division Bench on , declined to stay a single-judge order permitting the manufacture of Semaglutide—the key active ingredient in Novo Nordisk’s blockbuster drugs Ozempic, Wegovy, and Rybelsus—strictly for export from India. This ruling, rooted in doubts over the validity of Novo Nordisk’s , underscores India’s evolving jurisprudence on pharmaceutical intellectual property, particularly in the high-stakes GLP-1 receptor agonist market amid a global surge in demand for diabetes and obesity treatments.
The decision not only allows Dr Reddy’s to proceed with production for international markets but also signals judicial skepticism toward patent " " tactics, where incremental modifications to known compounds are sought to extend exclusivity. With Semaglutide at the heart of a multi-billion-dollar industry—Novo Nordisk reported over $14 billion in Ozempic sales in 2023 alone—this case could reshape competitive dynamics for generic entrants.
Background on the Dispute
Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has revolutionized treatment for type-2 diabetes and obesity. Marketed by Danish pharma giant Novo Nordisk under brands like Ozempic (injectable for diabetes), Wegovy (higher-dose for weight loss), and Rybelsus (oral formulation), it mimics gut hormones to regulate blood sugar and appetite. The drug’s meteoric rise, fueled by celebrity endorsements and clinical trial successes, has positioned GLP-1s as a projected $100 billion market by 2030.
Novo Nordisk’s intellectual property strategy in India hinges on a specifically claiming Semaglutide. This followed an earlier —covering a broader class of GLP-1 compounds—which expired in . Last year, upon learning of Dr Reddy’s plans to produce the compound, Novo filed a patent infringement suit in the , seeking to restrain all manufacturing, including for exports.
Dr Reddy’s mounted a robust defense, arguing the lacked and under . Citing the expired and extant scientific literature as , they contended that Semaglutide represented an obvious modification, failing the threshold required for patentability.
This clash exemplifies perennial tensions in Indian pharma IP: innovators like Novo accuse generics of freeloading, while defendants highlight India’s pro-access patent regime, shaped by (barring incremental innovations without enhanced efficacy) and post-grant oppositions.
The Single-Judge Ruling
On
, a single-judge Bench of the
delivered a pivotal interim order. The court held that
"the Semaglutide patent appeared vulnerable to revocation under
."
It observed that
"the compound modification leading to the creation of Semaglutide seemed obvious, in light of
, including the earlier
and scientific literature."
Section 64 empowers revocation on grounds like lack of (anticipated by prior publication) or (obvious to a person skilled in the art). The judge’s findings leaned heavily on the genus-species interplay: once the broader genus lapses, species claims built on routine tweaks often crumble under obviousness scrutiny.
Consequently, the court dismissed Novo’s application for an injunction against Dr Reddy’s, instead granting permission for
"manufacture [of] Semaglutide in India strictly for export purposes, clarifying that the permission did not extend to domestic sale."
This export carve-out reflects a nuanced balance—safeguarding India’s generic export industry (worth $25 billion annually) while deferring domestic market competition until final adjudication.
Division Bench Upholds the Order
Novo Nordisk swiftly appealed, seeking a stay. However, on
, the Division Bench refused, opining that
"the appeal itself should be heard finally."
This expedited approach—bypassing interim relief—signals judicial confidence in the single judge’s analysis and a push for swift resolution in commercial disputes.
By declining the stay, the Bench preserved the status quo: Dr Reddy’s can ramp up export-oriented production, potentially capturing shares in cost-sensitive markets like the US and Europe, where Semaglutide generics are eagerly awaited post-patent cliffs.
Legal Analysis: , , and Obviousness
At its core, this ruling hinges on foundational patent principles. demands absolute originality; any prior disclosure suffices for invalidation. Here, the expired disclosed the chemical scaffold, rendering Semaglutide’s side-chain tweak non-novel.
—India’s test—asks whether the invention would be obvious to a skilled artisan ( ). Courts apply the (Glivec case) framework: purposive construction, common general knowledge, and hindsight avoidance. The single judge’s invocation of "scientific literature" alongside the suggests Semaglutide’s modifications (e.g., lipidation for half-life extension) were predictable extrapolations.
This echoes precedents like (Tarceva), where species claims post-genus expiry were invalidated. Critically, the export restriction aligns with , permitting extraterritorial production under infringement laws, as long as no Indian sales occur—upholding ’s territoriality.
Interim injunctions in patent suits demand a conjoined reading of case, , and ( ). Novo faltered on all: weak patent validity, Dr Reddy’s export focus tilting convenience, and no evidence of irreparable harm from non-domestic activity.
Commercial and Strategic Implications
For Dr Reddy’s, this is a strategic coup. India’s API (active pharmaceutical ingredient) exports to formulated drugs enable vertical integration, slashing costs for affiliates abroad. With Semaglutide’s US patents expiring in 2031-2032, early mover advantage via Indian production positions them competitively.
Novo Nordisk faces headwinds: lost exclusivity in export hubs erodes pricing power, especially as copycats flood emerging markets. Globally, this bolsters narratives of India as the "pharmacy of the world," with 20% of US generics sourced here.
The GLP-1 boom amplifies stakes—Eli Lilly’s Mounjaro rivals Ozempic, but supply shortages persist. Generic inflows could democratize access, though quality concerns linger.
Broader Impact on Indian Patent Landscape
This decision reinforces India’s TRIPS-compliant yet public-health-oriented IP regime. Post-2005 product patent restoration, courts vigilantly police , as in (Valcyte). Fast-tracking appeals via Division Benches streamlines IP litigation, clogged by 50,000+ pendings.
For practitioners: Expect heightened scrutiny of genus-species chains; export-only injunctions as a compromise tool; bolstered Section 64 challenges in oppositions/revocations. Pharma litigators must marshal robust dossiers early.
Strategically, innovators may pivot to formulation/process patents or efficacy data, while generics leverage compulsory licensing (e.g., Bayer’s Nexavar).
Conclusion
The ’s rulings mark a pro-competitive tilt in Semaglutide’s saga, prioritizing patent rigor over provisional monopolies. As the appeal proceeds to final hearing, stakeholders watch closely: a revocation could unlock floods of affordable GLP-1s, transforming global health economics. For Indian IP law, it cements a legacy of balancing innovation incentives with accessible medicines.
